Target: Amyloid Beta 1-42 Oligomer
Conjugate: Unconjugated
Product Type: Recombinant Monoclonal
Clone Number: 2F9
Immunogen: Amyloid beta 1-42 oligomers (StressMarq Catalog# SPR-488)
Swiss-Prot: P05067
Purification: Protein A Purified
Storage Buffer: PBS pH 7.4, 50% glycerol, 0.09% sodium azide. *Storage buffer may change when conjugated
Concentration: 0.5mg/ml
Specificity: Amyloid Beta 1-42 oligomers
Cellular Localization: Membrane (Secreted)
Tissue Specificity: CNS, Blood
Scientific Background: Our amyloid beta oligomer antibody (clone 2F9) has been tested for specificity against synthetic AB 1-42 aggregates, with higher specificity to oligomers demonstrated. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (1). The immunogen used was our Amyloid Beta 1-42 (Aβ42) Oligomers are generated from Amyloid Beta Peptide 1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) as previously published (2,3).
References: 1. Panza et al. 2019. Nat Rev Neurol. 15:73-88 https://doi.org/10.1038/s41582-018-0116-62. Stine et al. 2003. JBC. 278(13):11612-22. doi: 10.1074/jbc.M2102072003. Ahmed et al. 2010. Nature Structural & Molecular Biology. 17(5):561 doi: 10.1038/nsmb.1799
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
